The translocation t(4;14) can be present only in minor subclones in multiple myeloma

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4634-4637

  Hébraud, Benjamin ^a,b   Caillot, Denis ^d   Corre, Jill ^a,b   Marit, Gérald ^e   Hulin, Cyrille ^g   Leleu, Xavier ^h   Lodé, Laurence ⁱ   Wetterwald, Marc ^j   Dib, Mamoun ^k   Rodon, Philippe ^l   Voillat, Laurent ^m   Royer, Bruno ⁿ   Voog, Eric ^o   Fitoussi, Olivier ^f   Stoppa, Anne Marie ^p   Garderet, Laurent ^q   Kolb, Brigitte ^r   Maigre, Michel ^s   Boullanger, Nadine ^m   Allangba, Olivier ^m   Karlin, Lionel ^t   Daguindau, Nicolas ^u   Legros, Laurence ^v   Sohn, Claudine ^w   Joubert, Marie Véronique ^a,b   Lenain, Pascal ^x   Facon, Thierry ^h   Attal, Michel ^c   Moreau, Philippe ⁱ   Avet Loiseau, Hervé ^a,b   more..

^a Unité de Génomique du Myélome   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f Clinique Bordeaux Nord   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j CHU   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l Service d'Hématologie   (France)

^m Service d'Hématologie   (France)

ⁿ AMIENS UNIVERSITY HOSPITAL   (France)

^o Clinique Victor Hugo   (France)

^p INSTITUT PAOLI CALMETTES   (France)

^q HÔPITAL SAINT ANTOINE   (France)

^r REIMS UNIVERSITY HOSPITAL   (France)

^s CH   (France)

^t HOSPICES CIVILS DE LYON   (France)

^u CH   (France)

^v UNIVERSITY HOSPITAL OF NICE   (France)

^w Service d'Hématologie   (France)

^x Centre Becquerel   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHIMERA; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CLONE; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; BASE SEQUENCE; CELL LINEAGE; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; TRANSLOCATION, GENETIC;

EID: 84883469602     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3866     Document Type: Article

References (15)

1. Avet-Loiseau H, Magrangeas F, Moreau P, Attal M, Facon T, Anderson K, et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 2011;29:1893-7.
2. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303. (Pubitemid 40967205)
3. Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013;27:473-81.
4. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060-6.
5. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-76.
6. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489-95. (Pubitemid 46572539)
7. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000;60:4058-61. (Pubitemid 30636584)
8. Kuehl M, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87. (Pubitemid 37328787)
9. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature 2008;454:226-31. (Pubitemid 351969894)
10. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
11. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009;23:1941-56.
12. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48.
13. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84. (Pubitemid 46425864)
14. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008;111:968-9.
15. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010;116:2543-53.